Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The COVID-19 pandemic is becoming prolonged leading to more deaths and new variants. The company should generate higher net income and revenue in 2022, supporting a stronger net cash position after buybacks.

Moderna Is Growing With The Vaccine Income

Shares of Moderna Inc. MRNA, -0.85% were down 0.5% in premarket trading on Wednesday after the company said it began dosing participants in a Phase 1 clinical trial evaluating the company's experimental Epstein-Barr virus vaccine. The virus causes mononucleosis, also called mono, and is associated with a higher risk of multiple sclerosis and some lymphoproliferative disorders.

Moderna begins Phase 1 study of its Epstein-Barr virus vaccine candidate

Moderna expects to enroll approximately 270 participants in the U.S. EBV is a major cause of infectious mononucleosis, which can debilitate patients for weeks to months; there is no approved vaccine to prevent EBV EBV can also lead to lifelong medical conditions and is associated with an increased risk of developing multiple sclerosis, certain lymphoproliferative disorders, cancers, and autoimmune diseases Moderna now has a portfolio of two vaccines against latent viruses in the clinic: CMV and EBV CAMBRIDGE, MA / ACCESSWIRE / January 5, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus (EBV) vaccine candidate. The study is known as Eclipse.

Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine

After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.

Is Now a Good Time to Buy Moderna Stock?

CAMBRIDGE, MA / ACCESSWIRE/ January 4, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will participate in a fireside chat at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on Thursday, January 6th at 2:00 p.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.

Moderna to Present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference

News that Moderna Inc. ( MRNA , Financial) had shipped about 800 million doses of its Covid-19 vaccine to more than 60 countries in 2021 -- and more than tripled the amount of cash and cash equivalents it held – caught Wall Street's eye on Tuesday morning.

Moderna Injects Analysts, Investors With Confidence

Tesla

The winners on the first trading day of 2021 mostly went on to outperform the S&P 500. The losers did not.

Tesla and Moderna Started 2022 Very Differently. What History Says Happens Next.

Moderna stock had a banner year of sorts in 2021, as the company quickly scaled up production and distribution of its Covid-19 shot. Moderna's financial performance has also been great, with sales likely to grow over 13x year-over-year to more than $17 billion for 2021, with profits likely.

Should You Buy Moderna Stock At $250?

Moderna Inc. MRNA, -7.45% said in a letter to shareholders disclosed Tuesday, Chief Executive Stéphane Bancel said the biotechnology company had shipped about 800 million doses of its COVID-19 vaccine to more than 60 countries in 2021, and more than tripled the amount of cash and cash equivalents it held. Meanwhile, the stock dropped 1.2% in premarket trading, after dropping 7.5% on Monday, and tumbling 27.9% in December.

Moderna shipped 800 million COVID vaccines last year, more than tripled its cash position but stock falls again

Novavax

Both of these coronavirus vaccine innovators have plenty of upside in 2022.

Better Buy: Novavax vs. Moderna

Bath and Body Works

Devon Energy

Ford Motor Company

Diamondback Energy

Fortinet

Marathon Oil

Nucor

NVIDIA

Signature Bank

The "Mad Money" host said he believes many of the S&P 500's biggest winners in 2021 may keep thriving this year.

Jim Cramer's 2022 outlook for the S&P 500's 10 biggest winners last year

BioNTech SE

Pfizer

Investors appear to be seeing a future where COVID-19 vaccines aren't needed nearly as much.

Why Pfizer, BioNTech, and Moderna Stocks Are Falling Today

CAMBRIDGE, MA / ACCESSWIRE / January 3, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at the virtual 40th annual J.P. Morgan Healthcare Conference on Monday, January 10th at 8:15 a.m.

Moderna to Provide Business and Pipeline Updates at the 2022 J.P. Morgan Healthcare Conference

Xeris Biopharma Holdings

Find out what's moving markets on the last day of the year.

Moderna's on the Rise, but This Small Biotech Is the Nasdaq's Big Winner on New Year's Eve

Gartner

The S&P 500 delivered one of its best years in recent history in 2021, gaining more than 27%. Most U.S. investors had a lot of winners in their portfolios this year, but some stocks certainly performed better than others.

10 Best Performing S&P 500 Stocks Of 2021

Codex DNA

Gilead Sciences

Check out these biotech stocks gaining investor interest now.

3 Biotech Stocks To Watch In 2022

One coronavirus vaccine will apparently be authorized as a booster for younger people in the U.S.

Why Pfizer, BioNTech, and Moderna Shot Higher Today

AbbVie

Accenture Plc

Citigroup

Coinbase

Cognizant Technology Solutions

Kulicke & Soffa Industries

TimkenSteel

This is the 22nd year I've published my top 10 stock picks.

My Top 10 Stocks For 2022

Vaccine stocks have been in a recent downfall, and getting hit particularly hard are Moderna Inc (NASDAQ:MRNA) and BioNTech SE (NASDAQ:BNTX).

Vaccine Sector Rally Over for These 2 Stocks

Fulgent Genetics

The pandemic may have brought these companies to prominence, but there's much more to the story.

My 2 Favorite Healthcare Stocks for 2022

SPDR S&P 500 ETF Trust

The S&P 500 has been enjoying smooth trading this year with the benchmark reaching the 69th record close of the year.

5 Stocks That Have Powered the S&P 500 ETF in 2021

Shares have dropped 16% over the past five days.

Moderna Stock Set to Drop for Sixth Straight Session

Moderna stock had a solid 2021 as the company quickly scaled up production and distribution of its much-sought-after Covid-19 shot as countries undertook one of the largest vaccination drives in history. Although the stock saw considerable volatility, falling by almost 48% from highs of about.

What Will 2022 Have In Store For Moderna Stock?

Agreement includes 15 million doses for delivery in the third quarter of 2022 and 5 million doses for delivery in the fourth quarter of 2022 CAMBRIDGE, MA / ACCESSWIRE / December 27, 2021 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a revised supply agreement with the government of South Korea for 20 million doses of Moderna's COVID-19 vaccine or an updated booster vaccine candidate, if authorized. Under the terms of the agreement, Moderna expects to deliver 15 million doses in the third quarter of 2022 and 5 million doses in the fourth quarter of 2022.

Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna's COVID-19 Vaccine or Updated Booster Candidate in 2022

Surprise: They're both outside the tech industry.

News for Moderna Stock (MRNA)